Medium Branched-Chain Fatty Acids Could Be a Viable Anaplerotic Treatment Option for LCFAOD.

INFORM Lab Director, Dr. Al-Walid Moshen’s study, originally published in the Journal of Inherited Metabolic Disease, showed that medium branched-chain fatty acids could be a viable anaplerotic treatment option for long-chain fatty acid oxidation disorders (LCFAOD).

LCFAOD can be life-threatening, even with optimum care, because fatty acid oxidation is the main source of energy for the heart and is essential for the function of skeletal muscles.

This article was covered by The Rare Disease Advisor, the web’s premier source of news, perspectives and resources for clinicians who treat patients with rare diseases.

The full article can be found here.